ReviewCNS drugs2013
Management of alcohol dependence in patients with liver disease.
Review in CNS drugs, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed, 3 syntheses or guidelines pooled it, 108 citations in OpenAlex.
- Interventions to reduce the negative effects of alcohol consumption in older adults: a systematic review.BMC public health · 2018Pooled it
- Diagnosis and Treatment of Alcoholic Hepatitis: A Systematic Review.Alcoholism, clinical and experimental research · 2016Pooled it
- Acute alcoholic hepatitis, end stage alcoholic liver disease and liver transplantation: an Italian position statement.World journal of gastroenterology · 2014Guideline
- Enhancing care in alcohol-associated liver disease through peer support for alcohol use disorder.Hepatology communications · 2026Review
- Beyond diabetes and obesity: GLP-1 receptor agonists as multifunctional therapeutics across the steatotic liver disease spectrum.Frontiers in pharmacology · 2026Review
- Burden and determinants of upper gastrointestinal bleeding in cirrhotic patients: evidence from Sub-Saharan Africa, 2024.BMC gastroenterology · 2025Article
- Article
- Targeting gut health: Probiotics as promising therapeutics in alcohol-related liver disease management.AIMS microbiology · 2025Review
- Real-world analysis on the use of gamma-hydroxybutyric acid for alcohol withdrawal syndrome in hospitalized patients with diagnosis of cirrhosis.Internal and emergency medicine · 2025Observational
- Article
- Peroxisome proliferator-activated receptor agonists: A new hope towards the management of alcoholic liver disease.World journal of gastroenterology · 2024Article
- Alcohol dependence syndrome in patients with alcoholic liver disease: A cross sectional observational study.Industrial psychiatry journal · 2024Article
- Molecular mechanisms of alcohol's effects on the human body: A review and update.Journal of biochemical and molecular toxicology · 2023Review
- Testing a Digital Health App for Patients With Alcohol-Associated Liver Disease: Mixed Methods Usability Study.JMIR formative research · 2023Article
- A Review of the Characteristics of Clinical Trials and Potential Medications for Alcohol Dependence: Data Analysis from ClinicalTrials.gov.Medicina (Kaunas, Lithuania) · 2023Review
- Alcohol treatment discussions and clinical outcomes among patients with alcohol-related cirrhosis.BMC gastroenterology · 2023Article
- Management of alcohol use disorder in patients with cirrhosis in the setting of liver transplantation.Nature reviews. Gastroenterology & hepatology · 2022Review
- Liver Transplantation After Bariatric Surgery: a Clinical Cohort Study.Obesity surgery · 2021Article
- Pathophysiological Aspects of Alcohol Metabolism in the Liver.International journal of molecular sciences · 2021Review
- Alcohol-associated liver disease: A review on its pathophysiology, diagnosis and drug therapy.Toxicology reports · 2021Review
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
5 authors at 1 institution in 2 countries.
Funding
Abstract
Alcohol dependence represents a chronic and relapsing disease affecting nearly 10 % of the general population both in the USA and in Europe, with a widespread burden of morbidity and mortality. Alcohol dependence represents the most common cause of liver damage in the Western world. Although alcoholic liver disease is associated primarily with heavy drinking, continued alcohol consumption, even in low doses after the onset of liver disease, increases the risk of severe consequences, including mortality. Consequently, the ideal treatment of patients affected by alcohol dependence and alcoholic liver disease should aim at achieving long-term total alcohol abstinence and preventing relapse. The aim of the present review is to provide an update on the management of alcohol dependence in patients with alcoholic liver disease. Increasing evidence suggests the usefulness of psychosocial interventions and medications combined in order to reduce alcohol intake, promote abstinence and prevent relapse in alcohol-dependent patients. Disulfiram, naltrexone and acamprosate have been approved for this indication; gamma-hydroxybutyric acid (GHB) is approved in Italy and Austria. However, these drugs have not been tested in patients with advanced liver disease. Amongst other emerging pharmacotherapies for alcoholism, topiramate, ondansetron, and baclofen seem the most promising ones. Both topiramate and ondansetron have a safe profile in alcoholic patients; however, none of them has been tested in alcoholic patients with advanced liver disease. To date, baclofen represents the only anti-craving medication formally tested in a randomized clinical trial in alcoholic patients affected by liver cirrhosis, although additional confirmatory studies are warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.